PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 21–21 | Cite as

Omalizumab add-on therapy cost effective in severe asthma in Spain

Clinical study


  1. Entrenas Costa LM, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics-Open : 25 Jan 2019. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations